Publication | Closed Access

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

First-line TherapyHepatologyInternational Phase 3MedicinePathologyLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaRivoceranib Versus Sorafenib